首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1577057

幽门螺旋桿菌检测市场、机会、成长动力、产业趋势分析与预测，2024-2032

Helicobacter Pylori Testing Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月07日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年，全球幽门螺旋桿菌（H. Pylori）检测市值为4.83亿美元，预计在预测期内成长率为6.8%。这一增长的推动因素包括胃肠道疾病的盛行率不断上升、对即时检测 (PoC) 检测的需求不断增长以及非侵入性幽门螺旋桿菌检测的日益普及。

导致市场扩张的一个主要因素是胃溃疡病例的增加，这通常是由幽门螺旋桿菌感染引起的。压力、吸烟和过度使用非类固醇抗发炎药物 (NSAID) 等因素导致胃溃疡发病率增加，从而刺激了对诊断测试的需求。根据美国胃肠病学会 (AGA) 的数据，70-90% 的消化性溃疡患者体内都存在幽门螺旋桿菌，凸显了检测在管理溃疡相关疾病方面的关键作用。

幽门螺旋桿菌检测包括各种诊断程序，以检测胃肠道中细菌的存在。这种细菌与消化性溃疡、慢性胃炎以及某些情况下的胃癌等疾病有关。准确的检测有助于诊断感染、指导治疗和监测治疗效果。

市场依测试类型分为侵入性测试和非侵入性测试，到2023年，非侵入性测试将占据主导地位，占56.6%的市场份额。测验（SAT）因其不适感最小、见效快且适合所有年龄层而受到青睐。这些优势使非侵入性检测成为医疗保健提供者的热门选择，从而促进了细分市场的成长。

该市场按方法进一步分为 PoC 和实验室测试，后者占据最大的市场份额，2023 年价值 3.006 亿美元。）具有高灵敏度和特异性，在准确诊断幽门螺旋桿菌感染和监测抗生素抗药性方面发挥至关重要的作用。

就最终用途而言，诊断实验室在 2023 年占据市场主导地位，预计到 2032 年将达到 3.909 亿美元。

2023年北美幽门螺旋桿菌检测市值为1.701亿美元，预计复合年增长率为4.3%。该地区的市场成长是由胃癌盛行率上升和人们对幽门螺旋桿菌感染的认识不断提高以及诊断技术不断创新的支持所推动的。

产业生态系统分析
产业影响力
- 成长动力
  - 胃溃疡盛行率上升
  - 面临风险的老年人口不断增加
  - 对即时检测设备的需求不断增长
  - 非侵入性幽门螺旋桿菌检测的采用率不断上升
- 产业陷阱与挑战
  - 缺乏熟练的侵入性检测专业人员
  - 对幽门螺旋桿菌感染缺乏认识
成长潜力分析
报销场景
监管环境
技术景观
定价分析
波特的分析
PESTEL分析
差距分析
未来市场趋势

第 4 章：竞争格局

介绍
公司矩阵分析
公司市占率分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按测试类型，2021 - 2032 年

主要趋势
侵入性
- 组织学
- 尿素酶快速检测
- 惠普文化
非侵入性
- 血清学检测
- 尿素呼气试验
- 粪便/粪便抗原测试

第 6 章：市场估计与预测：依方法，2021 - 2032

主要趋势
护理点 (POC) 测试
基于实验室的测试

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
医院
诊所
诊断实验室
其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Abbott Laboratories
Advance Pharma
Avanos Corporate
Biohit Oyj
bioMerieux SA
Bio-Rad Laboratories, Inc.
Cardinal Health, Inc.
Epitope Diagnostics
Gulf Coast Scientific
Laboratory Corporation of America, Inc.
Medline Industries
Meridian Biosciences, Inc.
Quidel Corporation
TECHLAB, Inc
Thermo Fischer Scientific Corporation

简介目录

Product Code: 4408

The Global Helicobacter Pylori (H. Pylori) Testing Market was valued at USD 483 million in 2023, with a projected growth rate of 6.8% over the forecast period. This growth is driven by the increasing prevalence of gastrointestinal disorders, a rising demand for point-of-care (PoC) testing, and the growing adoption of non-invasive H. pylori tests.

A major factor contributing to the market's expansion is the rise in gastric ulcer cases, often caused by H. pylori infections. Factors such as stress, smoking, and the overuse of nonsteroidal anti-inflammatory drugs (NSAIDs) contribute to the increased incidence of gastric ulcers, fueling the demand for diagnostic testing. According to the American Gastroenterological Association (AGA), H. pylori is present in 70-90% of patients with peptic ulcers, highlighting the critical role of testing in managing ulcer-related conditions.

H. pylori testing encompasses various diagnostic procedures to detect the presence of the bacterium in the gastrointestinal tract. This bacterium is associated with conditions such as peptic ulcers, chronic gastritis, and, in some cases, gastric cancer. Accurate testing aids in diagnosing infections, guiding treatment, and monitoring therapy effectiveness.

The market is segmented by test type into invasive and non-invasive tests, with the non-invasive segment holding a dominant 56.6% market share in 2023. Non-invasive tests like the urea breath test (UBT) and stool antigen test (SAT) are preferred for their minimal discomfort, rapid results, and suitability for all age groups. These advantages make non-invasive tests a popular choice among healthcare providers, contributing to segment growth.

The market is further categorized by method into PoC and laboratory-based tests, with the latter accounting for the largest market share, valued at USD 300.6 million in 2023. Laboratory-based tests, such as polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA), offer high sensitivity and specificity, playing a crucial role in accurately diagnosing H. pylori infections and monitoring antibiotic resistance.

In terms of end use , diagnostic laboratories dominated the market in 2023 and are expected to reach USD 390.9 million by 2032. These laboratories offer specialized testing services, aiding in timely diagnoses and effective treatment planning.

The North American H. pylori testing market was valued at USD 170.1 million in 2023, with a projected CAGR of 4.3%. The region's market growth is driven by the rising prevalence of gastric cancers and growing awareness of H. pylori infections, supported by ongoing innovations in diagnostic technologies.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rise in prevalence of gastric ulcer
  - 3.2.1.2 Increasing geriatric population at risk
  - 3.2.1.3 Growing demand for point-of-care testing devices
  - 3.2.1.4 Rising adoption of non-invasive H. pylori testing
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Lack of skilled professionals for invasive testing
  - 3.2.2.2 Lack of awareness regarding H. pylori infection
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Regulatory landscape
3.6 Technology landscape
3.7 Pricing analysis
3.8 Porter's analysis
3.9 PESTEL analysis
3.10 Gap analysis
3.11 Future market trends

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Invasive
- 5.2.1 Histology
- 5.2.2 Rapid urease test
- 5.2.3 HP culture
5.3 Non-invasive
- 5.3.1 Serologic test
- 5.3.2 Urea breath test
- 5.3.3 Stool/fecal antigen test

Chapter 6 Market Estimates and Forecast, By Method, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Point of care (POC) tests
6.3 Laboratory based tests

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Clinics
7.4 Diagnostic laboratories
7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa